| Project/Area Number |
22590157
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
MATZNO Sumio 近畿大学, 薬学部, 教授 (30299094)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUYAMA Kenji 近畿大学, 薬学部, 教授 (00117251)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 臨床薬学 / 第2世代抗精神病薬 / メタボリック症候群 / レプチン / 細胞分化 / 脂肪細胞分化 / PPARγ / ストレスマーカー |
|---|
| Research Abstract |
In this study, the authors evaluated the effect of atypical antipsychotic agents (SGAs) on metabolic syndrome induction. Using neuroblastoma cell lines, one of SGAs, olanzapine, induced 5HT_<2C> mRNA transcription in PC12 autonomic neuroblastoma. Furthermore, olanzapine also induced PPAR_γ translation and subsequent fat accumulation in 3T3L1 mouse adipoblastoma cell line. These results suggest that olanzapine induces metabolic syndrome by synergistic effect of both an activation of sympathetic nervous system and an elevation of direct differentiation of adipose tissues.
|
